Join Us at ASM Microbe 2024
Are you attending ASM Microbe 2024? Join us at booth 903 to learn more about BD Diagnostic Solutions and BD Specimen Management. And how they can help to drive laboratory efficiencies, support clinical decisions through integrated automation and testing innovation to meet your evolving needs.
System and product demonstrations will include:
- Molecular Diagnostic Solutions
- Bloodstream Infection Solutions
- Lab Automation Solutions
- Specimen Management Solutions
Please join us for our scientific symposiums!
Enhancing patient care from high quality bloodstream infection detection to discharge: hospital onset bacteremia & fungemia
June 14th at 6:30 p.m.
![]() |
||
|
|
Dr. Kalvin Yu, MD, FIDSA |
|
Given the increasing clinical awareness of bacteremias and their significant impact on patients, BD Diagnostic Solutions recognizes the pivotal role of the microbiology lab and the need for quality tools to enable accurate and reliable detection of bloodstream infections. Hospital onset bacteremia and fungemia (HOB) is a new hospital-acquired infection (HAI) related quality metric proposed by the Centers for Disease Control and Prevention (CDC) to Centers for Medicare & Medicaid Services (CMS). The National Healthcare Safety Network (NHSN) has planned volunteer reporting of HOB sometime in 2024. In this educational symposium, recently published articles on the provisional HOB definition, sources of HOB, and associated clinical outcomes will be summarized. The importance of specimen collection and microbiology laboratory teams interfacing with antimicrobial stewardship programs to address HOB outcomes will be highlighted.
Targeted molecular panels: benefits for the laboratory and patients
June 15th at 6:30 p.m.
![]() |
![]() |
![]() |
|
Dr. Jose Alexander, MD, D(ABMM), FCCM, CIC, SM, MB(ASCP), BCMAS |
Dr. Jesse Young, PhD |
Dr. Christina Muzny, MD, MSPH, |
This symposium will have discussions on the benefits of targeted molecular testing for vaginitis, gastroenteritis, and respiratory infections. Topics include impact to laboratory workflow, performance versus traditional methods, co-infection rates, and considerations for choosing molecular panels. The impact of molecular testing on vaginitis, gastroenteritis, and respiratory testing will be discussed by Dr. Christina Muzny, MD, from the University of Alabama at Birmingham, Dr. Jose Alexander, MD from AdventHealth, and Dr. Jesse Young, PhD, from Tricore Reference Laboratories, respectively.
Urine trouble? Opportunities to improve urine-based diagnostics for infectious diseases presented
June 15th at 1:00 p.m.
![]() |
||
|
|
Dr. Melanie Yarbrough, PhD, DABMM, DABCC |
|
Recent advances in urine collection devices and diagnostic testing have provided opportunities for clinical laboratories to improve upon stagnant practices that may have deleterious effects on test utilization and result quality. Urine cultures are the gold standard for the diagnosis of urinary tract infection (UTI), one of the most common causes of bacterial infection, and therefore account for much of the workload in clinical microbiology laboratories. Contamination and workflow inefficiencies with urine specimens can lead to increased workload for the laboratory and antibiotic misuse in patients. Join Dr. Melanie L. Yarbrough to discuss the importance of pre-analytical variables in urine testing, describe the implementation and impact of reflex algorithms on urine culture utilization, and describe how laboratory-based initiatives to reduce unnecessary urine testing can improve workflow efficiency and impact patient care.





